Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand

ELI LILLY & Co

2025-Q3 EPS reported $15.56 revenue$45,887,000,000

Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.
Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.
Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.
Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.
U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.